Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation develops high-performance scientific instruments and analytical and diagnostic solutions for life science, applied, biopharma, microscopy, nanoanalysis, industrial, cleantech and semiconductor metrology markets.
Recurring news for BRKR includes earnings updates for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, product launches across NMR, microbiology, infection diagnostics, spatial biology and AFM-IR spectroscopy, and governance changes. Company announcements also cover platforms such as MALDI Biotyper, IR Biotyper, MyGenius PRO, GeoMx, CellScape, CosMx and Dimension IconIR.
Bruker Corporation (BRKR)/b) plans investor presentations at three upcoming healthcare conferences in September 2026.Senior leadership will present at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 9 at 8:00 a.m. Eastern Time, the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on September 16 at 10:45 a.m. Eastern Time, and the Bank of America Global Healthcare Conference in London on September 22 at 6:45 a.m. Eastern Time. Live audio webcasts and 30-day replays will be available in the Investor Relations section of the company website.
Bruker Energy & Supercon Technologies (BEST), a segment of Bruker (BRKR), and Luvata announced a strategic collaboration to supply high‑performance RRP superconductors for next‑generation magnetic confinement fusion demonstration and power plant projects worldwide.
The partners aim to expand industrial readiness and global manufacturing capacity for RRP niobium‑tin (Nb3Sn) superconducting wires, improving supply chain flexibility and resilience for large high‑field tokamak and stellarator programs. RRP technology, designed for magnetic fields of 12–20 Tesla, is already deployed in the LHC at CERN, ultra‑high field NMR magnets, and fusion projects. BEST and Luvata have previously supported ITER and the Wendelstein 7‑X stellarator, and RRP is being evaluated by Gauss Fusion for its high‑field stellarator and GIGA fusion power plant platform.
Bruker (Nasdaq: BRKR) announced an expanded strategic collaboration with Atinary Technologies, a pioneer in Self-Driving Labs and AI-driven R&D, and made a minority investment in Atinary; financial terms were not disclosed.
The collaboration aims to integrate Atinary’s code-free SDLabs agentic AI platform with Chemspeed configurable laboratory automation, Bruker analytical instruments, and SciY scientific software into closed-loop Design-Make-Test-Analyze-Learn workflows. These integrated systems are designed to automate complex chemical experimentation, generate high-quality, reproducible, AI-ready datasets, and accelerate discovery in pharmaceuticals, chemicals, energy, and materials. Joint demonstration labs in Basel and Boston showcase workflows featuring Chemspeed robotics and Bruker benchtop NMR for small-molecule synthesis and catalysis.
Bruker (Nasdaq: BRKR) announced a majority investment in MIMETAS, a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The deal expands Bruker’s post-genomic portfolio into human physiology-relevant Microphysiological Systems (MPS), also known as New Approach Methodologies (NAMs).
MIMETAS’ offerings include the OrganoPlate organ-on-a-chip platform, OrganoReady tissue and organoid products, instruments and contract research services. Bruker plans to integrate these human model systems with its proteomics, metabolomics, NMR, preclinical imaging and spatial biology technologies. Financial terms were not disclosed, and MIMETAS will retain its brand and management.
Bruker (Nasdaq: BRKR) reported Q2 2026 revenue of $838.5 million, up 5.2% year-over-year and 2.8% organically (3.4% excluding tariff refunds). Bruker Scientific Instruments revenue was $767.3 million, up 4.7% with 2.3% organic growth, while BEST revenue rose 11.9% to $74.2 million with 8.9% organic growth.
Q2 2026 BSI bookings grew 10% organically, with book-to-bill above 1.0x. Bruker recorded a GAAP operating loss of $(65.3) million, including a non-cash goodwill impairment of $134.9 million, versus $11.9 million GAAP operating income a year ago. Non-GAAP operating income increased to $118.5 million, with margin improving to 14.1% from 9.0%.
Q2 GAAP diluted loss per share was $(0.41), while non-GAAP diluted EPS rose to $0.49 from $0.32. For the first half of 2026, revenue increased 3.9% to $1.66 billion, with non-GAAP operating margin improving to 12.2%. Bruker updated its FY 2026 outlook only for currency and tax, maintaining non-GAAP EPS guidance of $2.10–$2.15 (up 15%–17% year-over-year) on expected revenue of $3.54–$3.57 billion, implying 3%–4% reported growth and 1%–2% organic growth.
Bruker (Nasdaq: BRKR) will release its second quarter 2026 financial results before the market opens on Tuesday, August 4, 2026. A conference call and webcast to discuss results and business trends will be held at 9:00 a.m. EDT, with online, telephone, pre-registration, and replay options provided.
Bruker (Nasdaq: BRKR) has acquired the DISQVER® clinical metagenomics platform from Noscendo, expanding its NGS-based infection detection portfolio. DISQVER provides advanced bioinformatics and reporting for rapid, comprehensive whole genome sequencing (WGS) analysis directly from cell-free human blood samples without prior cultivation.
According to Bruker, the DISQVER platform can search WGS data for more than 11,000 different microbes and parasites, delivering metagenomic next-generation sequencing (mNGS) results from blood-derived cell-free DNA in less than 24 hours after sample receipt. The approach targets research applications in bloodstream infections, sepsis, endocarditis and other severe infectious diseases. Following the acquisition, DISQVER will remain for research use only while Bruker pursues diagnostic registration. Financial terms were not disclosed, and DISQVER is not expected to be material to Bruker’s FY26 financial results.
Bruker (Nasdaq: BRKR) is highlighting its expanding Microbiology & Infection Diagnostics portfolio at ASM Microbe 2026, including MALDI Biotyper, IR Biotyper and MBioSEQ workflows. Enhancements feature an FDA‑cleared library of 549 microbial species, RUO/GP libraries covering 5,325 species, and tools for faster sepsis and bloodstream infection diagnostics.
According to Bruker, robust U.S. demand for MALDI Biotyper and IR Biotyper drove 140 new system placements in 2025, with double‑digit consumables growth and continued double‑digit U.S. microbiology growth into 2026.
Bruker (Nasdaq: BRKR) launched the new timsMRMS mass spectrometry platform for ultra-complex mixture analysis in the energy sector.
The system combines TIMS and extreme-resolution MRMS, offering >10M mass resolution, sub-ppm accuracy and isotope fine structure to support petroleomics, sustainable fuels and advanced energy storage research.
Bruker (Nasdaq: BRKR) announced major advances in 4D proteomics, metabolomics and air exposomics at ASMS. New launches include the timsMRMS ultra-high-resolution mass spectrometer, enhanced timsUltra AIP bottom-up proteomics workflows, and timsOmni top-down proteoform characterization with ~4x higher sensitivity.
Bruker also introduced AI-enabled OmniScape, ProteoScape and GlycoScape 2027 software, an early-access hybrid qualitative/quantitative 4D metabolomics workflow, and new TOFWERK airborne molecular contaminant TOF-MS tools, supported by a multi-million-dollar order from a leading global memory manufacturer.